Abstract
Adjuvants have been used to augment the immune response to antigens for more than 70 years. Ramon first demonstrated that it was possible to increase levels of diphtheria or tetanus antitoxin by the addition of bread crumbs, agar, tapioca, starch oil, lecithin, or saponin to the vaccines (1). In this chapter, an overview is provided of modern vaccine adjuvants as background for more detailed discussions of promising adjuvants in chapters to follow. After a more general discussion of adjuvants including their definition, mechanisms of action, safety, ideal characteristics, impediments to development, and preclinical and clinical regulatory issues, examples will be provided of experimental vaccine adjuvants that have entered clinical trial to enhance a variety of licensed and experimental vaccines in humans. For additional expositions on this complex subject and for a historical perspective, the reader is referred to recent textbooks on vaccine adjuvants (2–4) and a selection of useful review articles published over the past 18 years (5,10).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ramon, G. (1925) Sur l’augmentation anormale de l’antitoxine chez les chevaux producteurs de serum antidipherique. Bull. Soc. Cent. Med. Vet. 101, 227–234.
Spriggs, D. R. and Koff, W. C. (1991) Topics in Vaccine Adjuvant Research, CRC, Boco Raton, FL.
Stewart-Tull, D. E. S. (1989) Recommendations for the assessment of adjuvants (immunopotentiators) in Immunological Adjuvants and Vaccines (Gregoriadis, G., Allison, A. C., and Poste, G., eds.), Plenum, New York, pp. 213–226.
Powell, M. F. and Newman, M. J. (1995) Vaccine Design: The Subunit and Adjuvant Approach, Plenum, New York.
Edelman, R. (1980) Vaccine adjuvants. Rev. Infect. Dis. 2, 370–383.
Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben Efraim, and Gupta C. K. (1993) Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 11, 293–306.
Cooper, P. D. (1994) The selective induction of different immune responses by vaccine adjuvants, in Strategies in Vaccine Design (Ada, G. L., ed.), Landes, Austin, TX, pp. 125–158.
Hunter, R. L. and Lal, A. A. (1994) Copolymer adjuvants in malaria vaccine development. Am. J. Trop. Med. Hyg. 50, 52–58.
Gupta, R. K. and Siber, G. R. (1995) Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13, 1263–1276.
Cox, J. C. and Coulter, A. R. (1997) Adjuvants-a classification and review of their modes of action. Vaccine 15, 248–256.
Douglas, R. G., Jr. (1993) The children’s vaccine initiative-will it work? J. Infect. Dis. 168, 269–274.
Ramon, G. (1926) Procedes pour accroitre la production des antitoxines. Ann. Inst. Pasteur 40, 1–10.
Lesourd, B. M., Vincent-Falquet, J. C., Deslandes, D., Musset, M., and Moulias, R. (1988) Influenza vaccination in the elderly: improved antibody response with Imuthiol (Na diethyldithiocarbamate) adjuvant therapy. Int. J. Immunopharmacol. 10, 135–143.
Gravenstein, S., Duthie, E. H., Miller, B. A., Roecker, E., Drinka, P., Prathipati, K., and Ershler, W. B. (1989) Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J. Am. Geriatr. Soc. 37, 1–8.
Goodman, M. G. (1995) A new approach to vaccine adjuvants: Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine, in Vaccine Design: The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 581–610.
Lin, R., Tarr, P. E., and Jones, T. C. (1995) Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis. 21, 1439–1449.
Hess, G., Kreiter, F., Kosters, W., and Deusch, K. (1996) The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J. Viral. Hepat. 3, 149–153.
Drabick, J. J., Tang, D. B., Moran, E. E., Trofa, A. F., Foster, J. S., and Zollinger, W. D. (1997) A randomized, placebo-controlled study of oral cimetidine as an immunopotentiator of parenteral immunization with a group B meningococcal vaccine. Vaccine 15, 1144–1148.
Evans, T. G., Judd, M. E., Dowell, T., Poe, S., Daynes, R. A., and Araneo, B. A. (1996) The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly. Vaccine 14, 1531–1537.
Edelman, R. and Tacket, C. O. (1990) Adjuvants. Int. Rev. Immunol. 7, 51–66.
Ockenhouse, C. F., Sun, P. F., Lanar, D. E., Wellde, B. T., Hall, B. T., Kester, K., et al. (1998) Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177, 1664–1673.
Stover, C. K., Bansal, G. P., Hanson, M. S., Burlein, J. E., Palaszynski, S. R., Young, J. F., et al. (1993) Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 178, 197–209.
MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K. E., Gluckman, S. J., Bagarazzi, M. L., et al. (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178, 92–100.
Hoffman, S. L., Edelman, R., Bryan, J. P., Schneider, I., Davis, J., Sedegah, M., et al. (1994) Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am. J. Trop. Med. Hyg. 51, 603–612.
Fries, L. F., Gordon, D. M., Richards, R. L., Egan, J. E., Hollingdale, M. R., et al. (1992) Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA 89, 358–362.
Lidgate, D. M. and Byars, N. E. (1995) Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines, in Vaccine Design: The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 313–324.
Wintsch, J., Chaignat, C. L., Braun, D. G., Jeannet, M., Stalder, H., Abrignani, S., et al. (1991) Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J. Infect. Dis. 163, 219–225.
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336, 86–91.
Levine, M. M. and Dougan, G. (1998) Optimism over vaccines administered via mucosal surfaces. Lancet 351, 1375–1376.
Tacket, C. O., Reid, R. H., Boedeker, E. C., Losonsky, G., Nataro, J. P., Bhagat, H., and Edelman, R. (1994) Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine 12, 1270–1274.
Lowell, G. H. (1997) Proteosomes for improved nasal, oral, or infectable vaccines, in New Generation Vaccines, 2nd ed. (Levine, M. M., Woodrow, G. C., Kaper, J. B., and Cobon, G. S., eds.), Marcel Dekker, Inc., New York, NY, pp. 193–206.
Chaicumpa, W., Chongsa-nguan, M., Kalambaheti, T., Wilairatana, P., Srimanote, P., Makakunkijcharoen, Y., et al. (1998) Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers. Vaccine 16, 678–684.
Moldoveanu, Z., Love-Homan, L., Huang, W. Q., and Krieg, A. M. (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216–1224.
Gould-Fogerite, S., Edghill-Smith, Y., Kheiri, M., Wang, Z., Das, K., Feketeova, E., Canki, M., and Mannino, R. J. (1994) Lipid matrix-based subunit vaccines: a structure-function approach to oral and parenteral immunization. AIDS Res. Hum. Retroviruses 10 Suppl. 2, S99–103.
Cryz, S. J., Jr. and Gluck, R. (1998) Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system. Dev. Biol. Stand. 92, 219–223.
Saldinger, P. F., Blum, A. L., and Corthesy-Theulaz, I. E. (1997) Perspectives of anti-H. pylori vaccination. J. Physiol. Pharmacol. 48 Suppl. 4, 59–65.
Glenn, G. M., Rao, M., Matyas, G. R., and Alving, C. R. (1998) Skin immunization made possible by cholera toxin [letter]. Nature 391, 851.
Gonzalez, C., Hone, D., Noriega, F. R., Tacket, C. O., Davis, J. R., Losonsky, G. et al. (1994) Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169, 927–931.
Edelman, R., Palmer, K., Russ, K. D., Secrest, H. P., Becker, J. A. Bodison, S. A., et al. (1998) Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: A candidate Lyme disease Vaccine. Vaccine, 17, 904–914.
Tacket, C. O., Losonsky, G., Lubeck, M. D., Davis, A. R., Mizutani, S., Horwith, G., et al. (1992) Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 10, 673–676.
Tacket, C. O., Mason, H. S., Losonsky, G., Clements, J. D., Levine, M. M., and Arntzen, C. J. (1998) Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature 4, 607–609.
Krieg, A. M. (1996) An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J. Lab. Clin. Med. 128, 128–133.
Newman, M. J. and Powell, M. F. (1995) Immunological and formulation design consideratins for subunit vaccines, in Vaccine Design: The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 1–42.
Newman, M. J., Wu, J. Y., Gardner, B. H., Munroe, K. J., Leombruno, D., Recchia, J., and Kensil, C. R. (1992) Saponin adjuvant induction of ovalbuminspecific CD8+cytotoxic T lymphocyte responses. J. Immunol. 148, 2357–2362.
Newman, M. J., Munroe, K. J., Anderson, C. A., Murphy, C. I., Panicali, D. L., Seals, J. R., et al. (1994) Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. AIDS Res. Hum. Retroviruses 10, 853–861.
Gupta, R. K. and Siber, G. R. (1994) Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals 22, 53–63.
Kensil, C. R., Newman, M. J., et al. (1993) The use of Stimulon adjuvant to boost vaccine response. Vaccine Res. 2, 273–282 (Abstr.).
Hui, G. S., Chang, S. P., Gibson, H., Hashimoto, A., Hashiro, C., Barr, P. J., and Kotani, S. (1991) Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. J. Immunol. 147, 3935–3941.
Kenney, J. S., Hughes, B. W., Masada, M. P., and Allison, A. C. (1989) Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Methods 121, 157–166.
Tam, J. P. (1988) Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 85, 5409–5413.
Nardin, E. H., Calvo-Calle, J. M., Oliveira, G. A., Clavijo, P., Nussenzweig, R., Simon, R., Zeng, W., and Rose, K. (1998) Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. Vaccine 16, 590–600.
Goldenthal, K. L., Cavagnaro, J. A., Alving, C. R., and Vogel, F. R. (1993) NCVDG working groups: Safety evaluation of vaccine adjuvants: National cooperative vaccine development meeting working group. AIDS Res. Hum. Retrovirus 9, S47–S51.
Bussiere, J. L., McCormick, G. C., and Green, J. D. (1995) Preclinical safety assessment considerations in vaccine development, in Vaccine Design:The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 61–79.
Schultz, N., Oratz, R., Chen, D., Zeleniuch-Jacquotte, A., Abeles, G., and Bystryn, J. C. (1995) Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 13, 503–508.
Keitel, W., Couch, R., Bond, N., Adair, S., Van Nest, G., and Dekker, C. (1993) Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11, 909–913.
Brewer, M. A., Edwards, K. M., Palmer, P. S., and Hinson, H. P. (1994) Bacille Calmette-Guerin immunization in normal healthy adults. J. Infect. Dis. 170, 476–479.
Kemp, E. B., Belshe, R. B., and Hoft, D. F. (1996) Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. J. Infect. Dis. 174, 113–119.
Gordon, D. M., Duffy, P. E., Heppner, D. G., Lyon, J. A., Williams, J. S., Scheumann, D., et al. (1996) Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Am. J. Trop. Med. Hyg. 55, 63–68.
Amador, R., Moreno, A., Murillo, L. A., Sierra, O., Saavedra, D., Rojas, M., et al. (1992) Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J. Infect. Dis. 166, 139–144.
Waters, R. V., Terrell, T. G., and Jones, G. H. (1986) Uveitis induction in the rabbit by muramyl dipeptides. Infect. Immun. 51, 816–825.
Allison, A. C. and Byars, N. E. (1991) Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 28, 279–284.
McElrath, M. J. (1994) Adjuvant effects on human immune responses in recipients of candidate HIV vaccines. IBC Conference, in Novel Vaccine Strategies for Mucosal Immunization, Genetic Approaches and Adjuvants, Rockville, MD, 24–26 (Abstr.).
Pearson, C. M. (1963) Experimental joint disease: Observations on adjuvantinduced arthritis. J. Chron. Dis. 16, 863–874 (Abstract).
Kleinau, S., Erlandsson, H., Holmdahl, R., and Klareskog, L. (1991) Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. J. Autoimmun. 4, 871–880.
Murray, R., Cohen, P., and Hardegree, M. C. (1972) Mineral oil adjuvants: biological and chemical studies. Ann. Allergy 30, 146–151.
Salk, J. and Salk, D. (1977) Control of influenza and poliomyelitis with killed virus vaccines. Science 195, 834–847.
Stuart-Harris, C. H. (1969) Adjuvant influenza vaccines. Bull. WHO 41, 617–621 (Abstract).
Beebe, G. W., Simon, A. H., and Vivona, S. (1972) Long-term mortality followup of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am. J. Epidemiol. 95, 337–346.
Page, W. F., Norman, J. E., and Benenson, A. S. (1993) Long-term follow-up of army recruits immunized with Freund’s incomplete adjuvanted vaccine. Vaccine Res. 2, 141–149.
Davenport, F. M. (1968) Seventeen years’ experience with mineral oil adjuvant influenza virus vaccines. Ann. Allergy 26, 288–292.
Keefer, M. C., Wolff, M., Gorse, G. J., Graham, B. S., Corey, L., Clements-Mann, M. L., et al. (1997) Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 13, 1163–1177.
Butler, N. R., Feng, S., Benson, P. F., et al. (1962) Response of infants to pertussis vaccine at one week and to poliomyelitis, diptheria, and tetanus vaccine at six months. Lancet 2, 112–114 (Abstract).
Cvjetanovic, B. and Uemura, K. (1965) The present status of field and laboratory studies of typhoid and paratyphoid vaccines with special reference to studies sponsored by the World Health Organization. Bull. WHO 32, 29–36 (Abstr.).
Woolridge, R. L., Grayston, J. T., Chang, I. A., et al. (1967) Long-term follow-up of the initial (1959-1960) trachoma vaccine field on Taiwan. Am. J. Ophthalmol. 63, 1650–1653 (Abstract).
Kasel, J. A., Couch, R. B., and Douglas, R.G., Jr. (1971) Antigenicity of alum and aqueous adenovirus hexon antigen vaccines in man. J. Immunol. 107, 916–919.
Davenport, F. M., Hennessy, A. V., and Askin, F. B. (1968) Lack of adjuvant effect of AIPO4 on purified influenza virus haemagglutinins in man. J. Immunol. 100, 1139–1140 (Abstr.).
Claesson, B. A., Trollfors, B., Lagergard, T., Taranger, J., Bryla, D., Otterman, G., et al. (1988) Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18-to 23-month-old children. J. Pediatr. 112, 695–702.
O’Hagan, D. T., Jeffery, H., and Davis, S. S. (1993) Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 11, 965–969.
Gupta, R. K., Rost, B. E., Relyveld, E., and Siber, G. R. (1995) Adjuvant properties of aluminum and calcium compounds, in Vaccine Design: The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York: 229–248.
World Health Organization (1977) Manual for the Production and Control of Vaccines-Tetanus Toxoid. BLD/UNDP/77.2 Rev.1 ed.
Jensen, O. M. and Koch, C. (1988) On the effect of AI(OH)3 as an immunological adjuvant. Acta Pathol. Microbiol. Immun. Scand. 96, 257–264 (Abstract).
Bumford, R. (1989) Aluminum salts: prospectives in their use as adjuvants, in Immunological Adjuvants and Vaccines (Gregoriadis, G., Allison, A. C., and Poste, G., eds.), Plenum, New York, pp. 35–41.
Hardegree, M. C., Pittman, M., and Maloney, C. J. (1972) Influence of mouse strain on the assayed potency (unitage) of tetanus toxoid. Appl. Microbiol. 24, 120–126.
Murphey-Corb, M., Ohkawa, S., Martin, L., et al. (1993) Comparative efficacy of a whole killed SIV vaccine in combination with various adjuvants, Sixth Annu. Meet. Nat. Cooperative Vaccine Dev. Group for AIDS (Abstract).
Tacket, C. O., Rennels, M. B., and Mattheis, M. J. (1997) Initial clinical evaluation of new vaccine candidates: phase 1 and 2 clinical trials of safety, immunogenicity, and preliminary efficacy, in New Generation Vaccines (Levine, M. M., Woodrow, G. C., Kaper, J. B., and Cobon, G. S., eds.), Marcel Dekker, New York, pp. 35–45.
U.S. Food and Drug Administration (1991) General Biological Products Standards, in Anonymous Code of Federal Regulations, Department of Health and Human Services, Bethesda, MD, pp. 43–53.
Davenport, L. W. (1995) Regulatory considerations in vaccine design, in Vaccine Design: The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 81–96.
Edelman, R. (1997) Adjuvants for the Future, in New Generation Vaccines (Levine, M. M., Woodrow, G. C., Kaper, J. B., and Cobon, G. S., eds.), Marcel Dekker, New York, pp. 173–192.
Hunsmann, G. (1995) Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. Vaccine 13, 295–300.
Ballou, W. R., Hoffman, S. L., Sherwood, J. A., Hollingdale, M. R., Neva, F. A., Hockmeyer, W. T., et al. (1987) Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1, 1277–1281.
Herrington, D. A., Clyde, D. F., Losonsky, G., Cortesia, M., Murphy, J. R., Davis, J., et al. (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328, 257–259.
Patarroyo, M. E., Amador, R., Clavijo, P., Moreno, A., Guzman, F., Romero, P., et al. (1988) A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332, 158–161.
Alonso, P. L., Smith, T., Schellenberg, J. R., Masanja, H., Mwankusye, S., Urassa, H., et al. (1994) Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344, 1175–1181.
Fries, L. F., Gordon, D. M., Schneider, I., Beier, J. C., Long, G. W., Gross, M., et al. (1992) Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect. Immun. 60, 1834–1839.
Brown, A. E., Singharaj, P., Webster, H. K., Pipithkul, J., Gordon, D. M., Boslego, J. W., et al. (1994) Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 12, 102–108.
Gordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., et al. (1995) Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite proteinhepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576–1585.
Heppner, D. G., Gordon, D. M., Gross, M., Wellde, B., Leitner, W., Krzych, U., et al. (1996) Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 174, 361–366.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Edelman, R. (2000). An Overview of Adjuvant Use. In: O’Hagan, D.T. (eds) Vaccine Adjuvants. Methods in Molecular Medicine™, vol 42. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-083-7:1
Download citation
DOI: https://doi.org/10.1385/1-59259-083-7:1
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-735-9
Online ISBN: 978-1-59259-083-4
eBook Packages: Springer Protocols